丁苯酞软胶囊联合瑞舒伐他汀治疗急性脑梗死患者的临床观察及对血清Lp-PLA2、IL-18、OX40L的影响  

Clinical observation of butylphthalide soft capsules combined with rosuvastatin in the treatment of patients with acute cerebral infarction and its influence on serum Lp-PLA2,IL-18,OX40L

作　　者：南楚 黄爱玲 陈维萍 刘怡伽 董超前 苏丹颖[1] NAN Chu;HUANG Ailing;CHEN Weiping(The Fourth Affiliated Hospital of Harbin Medical University,Harbin 150000,China)

机构地区：[1]哈尔滨医科大学附属第四医院,黑龙江哈尔滨150000

出　　处：《中风与神经疾病杂志》2023年第3期266-269,共4页Journal of Apoplexy and Nervous Diseases

摘　　要：目的探讨丁苯酞软胶囊联合瑞舒伐他汀治疗急性脑梗死患者的临床观察及对血清Lp-PLA2、IL-18、OX40L的影响。方法收集2021年9月-2022年1月期间,哈尔滨医科大学附属第四医院神经内科病区及门诊收治的急性脑梗死患者100例,随机将其分为对照组和治疗组,各组50例。对照组予以基础治疗及瑞舒伐他汀(10 mg/次,1次/d),治疗组在其基础上再予以丁苯酞软胶囊(0.2 g/次,3次/d)。根据卒中量表(NIHSS)评分和Barthel指数(Barthel Index)评估两组患者治疗前与治疗90 d后神经功能缺损程度和基础日常生活能力,比较两组治疗前后的血清Lp-PLA2、IL-18、OX40L水平。结果治疗组临床总有效率为94.00%高于对照组的80.00%(P<0.05)。治疗90 d后,两组NIHSS评分、Lp-PLA2水平均降低,Barthel指数评分均升高,并且治疗组改善显著优于对照组(P<0.05);治疗组NIHSS评分高分组患者血清Lp-PLA2水平高于低分组(P<0.05)。两组患者治疗前的NIHSS评分、Barthel指数以及治疗前后IL-18、OX40L水平无统计学差异(P>0.05)。两组不良反应发生率分别为12.00%和16.00%,无显著差异(P>0.05)。结论丁苯酞软胶囊联合瑞舒伐他汀治疗具有良好的疗效和安全性,可明显促进患者神经功能恢复,提高日常生活能力,并且降低血清Lp-PLA2水平。Objective To investigate clinical observation of butylphthalide soft capsules combined with rosuvastatin in the treatment of patients with acute cerebral infarction and its influence on serum Lp-PLA2,IL-18,OX40L.Methods From September 2021 to January 2022,we collected 100 patients with acute cerebral infarction who were admitted to the neurology ward and outpatient department of our hospital.These patients were randomly divided into two groups:the control group and the treatment group,with 50 patients in each group.The control group was given basic treatment and rosuvastatin(10 mg/time,1 time/d),while the treatment group was additionally given butylphthalide soft capsule(0.2 g/time,3 times/d).According to the National Institutes of Health Stroke Scale(NIHSS)score and Barthel Index,the degree of neurological deficit and ability of daily life of the two groups were evaluated before and 90 days after treatment,and the levels of serum Lp-PLA2,IL-18,OX40L were compared.Results The total clinical efficacies in the treatment group were 94.00%,higher than 80.00%in the control group(P<0.05).After 90 d treatment,NIHSS score and Lp-PLA2 level decreased,Barthel index increased,and the improvement in the treatment group was significantly better than those in the control group(P<0.05).The level of serum Lp-PLA2 was higher in patients with high NIHSS scores in the treatment group than in patients with low NIHSS scores.Before treatment,there were no significant differences between the two groups in NIHSS score,Barthel index,IL-18 levels,and OX40L levels.After treatment,there were also no significant differences between the two groups in IL-18 and OX40L levels(P>0.05).The incidence of adverse reactions in the two groups was 12.00%and 16.00%,respectively(P>0.05).Conclusion The combination of butylphthalide soft capsule and rosuvastatin has good efficacy and safety,which can significantly promote the recovery of neurological function,improve the ability of daily life,and reduce the level of serum Lp-PLA2.

关 键 词：急性脑梗死 丁苯酞软胶囊 瑞舒伐他汀 LP-PLA2 IL-18 OX40L 

分 类 号：R743.3[医药卫生—神经病学与精神病学]